BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Seegene, Inc. to Participate in High Profile Panel on Companion Diagnostics at BIO-Europe 2012


11/8/2012 8:46:22 AM

GAITHERSBURG, MD and SEOUL, KOREA--(Marketwire - November 07, 2012) - Seegene Inc., (KOSDAQ: 096530) today announced that the company's Executive Vice President, David L. Dolinger, Ph.D., will participate in a high profile panel on companion diagnostics titled "Reinvigorating pharma pipelines through companion diagnostics" at BIO-Europe 2012, on November 12 in Hamburg, Germany.

Dolinger will be joined by fellow panelists Guy Greiveldinger, Director, BD&L and M&A, Novartis; Bruce Jordan, Senior International Product Manager, Roche Diagnostics; David de Graaf, CEO, Selventa; and moderator Toby Zaleski, Principal, Base Pair Group. BIO-Europe 2012 is the pre-eminent partnering meeting in the life science industry, attracting more than 3,000 executives who will engage in over 15,000 one-to-one partnering meetings.

"BIO-Europe 2012 is a great event to mark Seegene's strides into the companion diagnostic market. Seegene's advanced multiplex molecular diagnostic technologies are well suited to the development of new companion diagnostics tests that can effectively guide personalized therapeutic decision-making," said Dolinger. "Our ability to simultaneously detect multiple analytes from limited patient samples, in a single test, creates diagnostics capable of identifying patients who can truly benefit from the new therapeutics. It also enables our pharmaceutical partners to effectively stratify patient populations for more successful clinical trials."

About Seegene
Seegene is the world's leading developer of multiplex molecular technologies and multiplex clinical molecular diagnostics (M-MoDx). Seegene's core enabling technologies -- ACP™, DPO™, READ, and qTOCE™ -- are the foundation for M-MoDx tests that can simultaneously detect, differentiate and quantitate multiple targets with high sensitivity, specificity and reproducibility. Seegene's products detect multi-pathogens with great reliability and throughput, ultimately providing the most economical basis for saving time, labor and cost. Seegene's mission is to maintain leadership in molecular diagnostics for infectious diseases, genetics, pharmacogenetics, and oncology using innovative proprietary technologies.

For more information please visit www.seegene.com or call +301-762-9066.


Contacts:
Sang-Kil Lee, Ph.D.
Seegene Inc.
301-762-9066
Email Contact
or
Constantine Theodoropulos
Base Pair Group
617-816-4637
www.basepairgroup.com

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->